• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

News

Article

February 2, 2023

States With Legal Medical, Recreational Cannabis Policies Do Not Have Significantly Higher Rate of Psychosis-Related Outcomes

Author(s):

Erin Hunter, Assistant Editor

This is the largest known study to consider medical and recreational cannabis policies with US psychosis-related health care claims.

New research indicates that there is not a statistically significant association between rates of psychosis-related health outcomes and states that have medical and recreational cannabis polices, according to findings published in JAMA Network Open.

However, exploratory secondary analyses did observe higher rates of diagnosis for psychosis-related illness in states with recreational cannabis policies. The main subgroups who were diagnosed included men, individuals aged 55 to 64 years, and Asian beneficiaries.

“Results from fully-adjusted models showed that, compared with no legalization policy, states with legalization policies experienced no statistically significant increase in rates of psychosis-related diagnoses…or prescribed antipsychotics,” the study authors wrote.

There are 38 states that now permit medical cannabis use and nearly half of these states also permit recreational use. Since 2019, at least 48.2 million US citizens aged 12 years and older are believed to have used cannabis; however, controversy surrounds its effect on psychotic disorders, which can inhibit important societal functions such as education and employment maintenance.

Investigators previously linked heavy use of cannabis with the tripling of the risk for developing schizophrenia compared to non-users and increasing the risk of self-harm, especially in men under 40 years of age.

The authors of the current study conducted a retrospective analysis to examine an association between state cannabis legalization and rates of psychosis-related health care claims in privately insured individuals. They hypothesized that states with legal recreational and commercialization policies would have a higher number of patients with psychosis-related illness and antipsychotic prescriptions.

Using the Optum Clinformatics Data Mart Database, researchers evaluated 63,680,589 beneficiaries and their insurance claims, looking at the association between claims for antipsychotics and states that have legalized cannabis.

The team observed no significant increase in the rate of people diagnosed with a psychosis-related illness in states with policies that legalize cannabis, be it for medical or recreational use. They also did not observe a significant increase in prescriptions for antipsychotics.

A subgroup analysis provided insight about the use of cannabis and psychosis-related diagnosis among different sexes, ages, races, and ethnicities. This served as a significant predictor of mental health care, with men aged 55 to 64 years observed to use services more than younger and older adults. Race and ethnicity were not reported as often, paving the way for future studies, according to the investigators.

Study limitations included that the findings may not be generalizable to uninsured patients, and there may be confounding variables, such as the relocation of psychosis patients to states that legalize cannabis. Additionally, no adjustments were made for multiple comparisons in future analyses, and the study included a small sample size.

“As states continue to introduce cannabis policies, the implications of state cannabis legalization for psychotic disorders warrants continued study, particularly in data settings where direct measures of disease onset and severity are available,” the study authors wrote.

Reference

Elser H, Humphreys K, Kiang M, et al. State Cannabis Legalization and Psychosis-Related Health Care Utilization. January 25, 2023. JAMA Netw Open. 2023;6(1):e2252689. doi:10.1001/jamanetworkopen.2022.52689

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Psychiatric pharmacist -- Image credit: HBS | stock.adobe.com
Image credit:  Artur | stock.adobe.com
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Related Content
Advertisement
Ivermectin tablets
July 11th 2025

Four States Pass Laws Allowing OTC Ivermectin, More States Pending Legislation

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Importance of Mental Health for Patients and Pharmacists Alike
July 10th 2025

Pharmacy Focus: Importance of Mental Health for Patients and Pharmacists Alike

Gustavo Alva, MD Luke Halpern, Assistant Editor
Pharmacies Lead the Way in Vaccine Equity and Access With Scalable, Sustainable Models
July 10th 2025

Pharmacies Lead the Way in Vaccine Equity and Access With Scalable, Sustainable Models

Aislinn Antrim, Managing Editor
Pharmacy Focus: Navigating Seasonal Allergies
May 28th 2025

Pharmacy Focus: Navigating Seasonal Allergies

Luke Halpern, Assistant Editor Derek Webb, PharmD
Medical form, diagnosis schizophrenia | Image Credit: Rawf8 | stock.adobe.com
July 10th 2025

Lumateperone Submits Application for Schizophrenia Indication to FDA for Supplemental New Drug

Danielle Valletti, Assistant Editor
Abstract representation of cholesterol levels with colorful particles floating. This illustrates complexity of blood components and cholesterol
July 10th 2025

With Proper Adherence to Cholesterol-Lowering Drugs, Thousands of Cardiovascular Events Could Be Avoided

Luke Halpern, Assistant Editor
Related Content
Advertisement
Ivermectin tablets
July 11th 2025

Four States Pass Laws Allowing OTC Ivermectin, More States Pending Legislation

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Importance of Mental Health for Patients and Pharmacists Alike
July 10th 2025

Pharmacy Focus: Importance of Mental Health for Patients and Pharmacists Alike

Gustavo Alva, MD Luke Halpern, Assistant Editor
Pharmacies Lead the Way in Vaccine Equity and Access With Scalable, Sustainable Models
July 10th 2025

Pharmacies Lead the Way in Vaccine Equity and Access With Scalable, Sustainable Models

Aislinn Antrim, Managing Editor
Pharmacy Focus: Navigating Seasonal Allergies
May 28th 2025

Pharmacy Focus: Navigating Seasonal Allergies

Luke Halpern, Assistant Editor Derek Webb, PharmD
Medical form, diagnosis schizophrenia | Image Credit: Rawf8 | stock.adobe.com
July 10th 2025

Lumateperone Submits Application for Schizophrenia Indication to FDA for Supplemental New Drug

Danielle Valletti, Assistant Editor
Abstract representation of cholesterol levels with colorful particles floating. This illustrates complexity of blood components and cholesterol
July 10th 2025

With Proper Adherence to Cholesterol-Lowering Drugs, Thousands of Cardiovascular Events Could Be Avoided

Luke Halpern, Assistant Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.